Portal de investigación
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rodríguez-Moranta F
- Argüelles-Arias F
- Hinojosa Del Val J
- Martín-Arranz MD
- Menchén Viso L
- Muñoz Núñez F
- Ricart Gómez E
- Sánchez-Hernández JG
- Valdés-Delgado T
- Guardiola Capón J
- Barreiro-de Acosta M
- Mañosa Ciria M
- Zabana Abdo Y
- Gutiérrez Casbas A
Grupos
Abstract
The treatment of inflammatory bowel disease has undergone a significant transformation following the introduction of biologic drugs. Thanks to these drugs, treatment goals have evolved from clinical response and remission to more ambitious objectives, such as endoscopic or radiologic remission. However, even though biologics are highly effective, a significant percentage of patients will not achieve an initial response or may lose it over time. We know that there is a direct relationship between the trough concentrations of the biologic and its therapeutic efficacy, with more demanding therapeutic goals requiring higher drug levels, and inadequate exposure being common. Therapeutic drug monitoring of biologic medications, along with pharmacokinetic models, provides us with the possibility of offering a personalized approach to treatment for patients with IBD. Over the past few years, relevant information has accumulated regarding its utility during or after induction, as well as in the maintenance of biologic treatment, in reactive or proactive strategies, and prior to withdrawal or treatment de-escalation. The aim of this document is to establish recommendations regarding the utility of therapeutic drug monitoring of biologics in patients with inflammatory bowel disease, in different clinical practice scenarios, and to identify areas where its utility is evident, promising, or controversial.
Copyright © 2024 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0210-5705, 0210-5705
- Tipo:
- Practice Guideline
- Páginas:
- 522-552
- PubMed:
- 38311005
- Factor de Impacto:
- 0,280 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Gastroenterologia y Hepatologia ELSEVIER ESPANA SLU
Citas Recibidas en Web of Science: 21
Documentos
- No hay documentos
Filiaciones
Keywords
- Colitis ulcerosa, Crohn's disease, Enfermedad de Crohn, Enfermedad inflamatoria intestinal, Farmacocinética, Inflammatory bowel disease, Medicina personalizada, Modelo farmacocinético, Monitorización terapéutica de medicamentos, Personalized medicine, Pharmacokinetic model, Pharmacokinetics, Therapeutic drug monitoring, Ulcerative colitis
Campos de Estudio
Cita
Rodríguez F,Argüelles F,Hinojosa Del Val J,Iborra M,Martín MD,Menchén L,Muñoz F,Ricart E,Sánchez JG,Valdés T,Guardiola J,Barreiro M,Mañosa M,Zabana Y,Gutiérrez A. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis. Gastroenterol. Hepatol. 2024. 47(5):p. 522-552. IF:1,900. (3).